Hansa Biopharma AB (publ) (STO: HNSA)

Market Cap	3.74B
Revenue (ttm)	163.56M
Net Income (ttm)	-801.64M
Shares Out	67.81M
EPS (ttm)	-14.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	394,440
Open	52.00
Previous Close	51.95
Day's Range	51.45 - 57.30
52-Week Range	20.14 - 57.30
Beta	1.38
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 168
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: HNSA

Financial Performance

In 2023, HNSA's revenue was 134.09 million, a decrease of -13.22% compared to the previous year's 154.53 million. Losses were -831.72 million, 36.1% more than in 2022.